Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Fluticasone foroate/ vilanterol · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Subjects receiving fluticasone foroate/ vilanterol | EXPERIMENTAL | Eligible subjects will receive single dose of fluticasone foroate/ vilanterol combination treatment 800 micrograms/ 50 micrograms administered using a novel powder inhaler. There will be a washout period of 7 to 10 days between treatments. |
| Subjects receiving fluticasone foroate | ACTIVE_COMPARATOR | Eligible subjects will receive single dose of fluticasone foroate 800 micrograms administered using a novel powder inhaler. |
| Subjects receiving vilanterol | ACTIVE_COMPARATOR | Eligible subjects will receive single dose of vilanterol 50 micrograms administered using a novel powder inhaler. |
| Subjects receiving placebo | PLACEBO_COMPARATOR | Eligible subjects will receive single dose of placebo administered using a novel powder inhaler. |
| Name | Type | Description |
|---|---|---|
| Fluticasone foroate/ vilanterol | DRUG | Fluticasone foroate/ vilanterol 800 micrograms/ 50 micrograms will be available as dry powder inhaler. |
| Fluticasone foroate | DRUG | Fluticasone foroate 800 micrograms will be available as dry powder inhaler. |
| Vilanterol | DRUG | Vilanterol will be available as dry powder inhaler. |
| Placebo | DRUG | Placebo will be supplied as dry powder inhaler. |
Inclusion criteria: * Healthy male adults aged between 20 and 60 years inclusive * Healthy as determined by a responsible physician, based on a medical evaluation including history, physical examination, laboratory tests, and cardiac monitoring. A subject with a clinical abnormality or laboratory p...
Fluticasone foroate/vilanterol is an investigational small molecule combination drug being developed by GSK plc (ticker: GSK) for the treatment of asthma. It is currently in Phase 1 clinical development. The drug is administered via a novel inhaler device and has been studied in a completed clinical trial.
Fluticasone foroate/vilanterol is being developed for the treatment of asthma. It is an investigational combination therapy that has been studied in a Phase 1 clinical trial. The drug is not yet approved and remains in clinical development.
Fluticasone foroate/vilanterol is being developed by GSK plc, a pharmaceutical company listed on the stock exchange under the ticker GSK. The drug is currently in Phase 1 clinical development for the treatment of asthma.
Fluticasone foroate/vilanterol is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 1 trial has been completed, and the drug is still in the early stages of clinical testing.
Fluticasone foroate/vilanterol has been studied in one completed Phase 1 clinical trial, identified as NCT00625196. This trial compared the combination drug and its components separately using a novel inhaler device in healthy Japanese subjects. The trial enrolled 16 male participants and was conducted in Australia.
Fluticasone foroate/vilanterol is the drug name used in the clinical trial data. It is a combination of a corticosteroid and a long-acting beta agonist, developed for asthma. The drug is being studied under the name Fluticasone foroate/vilanterol in clinical trials.